
In America this year, over 21,000 new cases of ovarian cancer are expected, and over 14,000 deaths.
Once ovarian cancer has spread within the peritoneal cavity or to other organs, long-range survival is rare. However, shorter-term benefits can be obtained via several different chemotherapy regimens and one, essentially abdominal chemotherapy, has been very promising.
So why isn't it used more?